STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients
Open Access
- 1 March 2013
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 123 (4), 1580-1589
- https://doi.org/10.1172/jci60083
Abstract
Myeloid-derived suppressor cells (MDSC) play a key immunosuppressive role in various types of cancer, including head and neck squamous cell carcinoma (HNSCC). In this study, we characterized CD14+HLA-DR–/lo cells sorted from the tumors, draining lymph nodes, and peripheral blood of HNSCC patients. CD14+HLA-DR–/lo cells were phenotyped as CD11b+, CD33+, CD34+, arginase-I+, and ROS+. In all 3 compartments, they suppressed autologous, antigen-independent T cell proliferation in a differential manner. The abundance of MDSC correlated with stage, but did not correlate with previous treatment with radiation or subsites of HNSCC. Interestingly, MDSC from all 3 compartments showed high phosphorylated STAT3 levels that correlated with arginase-I expression levels and activity. Stattic, a STAT3-specific inhibitor, and STAT3-targeted siRNA abrogated MDSC’s suppressive function. Inhibition of STAT3 signaling also resulted in decreased arginase-I activity. Analysis of the human arginase-I promoter region showed multiple STAT3-binding elements, and ChIP demonstrated that phosphorylated STAT3 binds to multiple sites in the arginase-I promoter. Finally, rescue of arginase-I activity after STAT3 blockade restored MDSC’s suppressive function. Taken together, these results demonstrate that the suppressive function of arginase-I in both infiltrating and circulating MDSC is a downstream target of activated STAT3.Keywords
This publication has 53 references indexed in Scilit:
- Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancerOral Oncology, 2011
- Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1Cell, 2011
- Myeloid derived suppressor cells in human diseasesInternational Immunopharmacology, 2011
- Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13Cancer Immunology, Immunotherapy, 2011
- HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironmentThe Journal of Experimental Medicine, 2010
- Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neckHead & Neck, 2010
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapyCancer Immunology, Immunotherapy, 2008
- MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsisThe Journal of Experimental Medicine, 2007
- Regulation of immune responses by L-arginine metabolismNature Reviews Immunology, 2005